Nwam LLC Biogen Inc. Transaction History

Nwam LLC

$1.6 Billion
Q3 2024

A detailed history of Nwam LLC transactions in Biogen Inc. stock. As of the latest transaction made, Nwam LLC holds 1,152 shares of BIIB stock, worth $184,124. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,152

Previous 1,325 13.06%

Holding current value

$184,124

Previous $307,000 27.36%

% of portfolio

0.01%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$189.07 - $236.8 $32,709 - $40,966	-173 Reduced 13.06%	1,152 $223,000
Q2 2024 Jul 23, 2024	BUY	$190.52 - $236.72 $190 - $236	1 Added 0.08%	1,325 $307,000
Q1 2024 May 09, 2024	BUY	$212.02 - $267.71 $16,537 - $20,881	78 Added 6.26%	1,324 $285,000
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $17,807 - $21,435	80 Added 6.86%	1,246 $322,000
Q3 2023 Oct 31, 2023	SELL	$253.3 - $285.89 $23,303 - $26,301	-92 Reduced 7.31%	1,166 $299,000
Q2 2023 Aug 09, 2023	SELL	$275.25 - $318.06 $1,926 - $2,226	-7 Reduced 0.55%	1,258 $358,000
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $1,282 - $1,461	5 Added 0.4%	1,265 $351,000
Q4 2022 Feb 07, 2023	SELL	$252.44 - $306.72 $12,369 - $15,029	-49 Reduced 3.74%	1,260 $348,000
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $22,973 - $31,678	118 Added 9.91%	1,309 $350,000
Q2 2022 Aug 10, 2022	SELL	$187.54 - $223.02 $92,457 - $109,948	-493 Reduced 29.28%	1,191 $253,000
Q1 2022 May 12, 2022	SELL	$193.77 - $244.14 $1,162 - $1,464	-6 Reduced 0.36%	1,684 $355,000
Q4 2021 Feb 10, 2022	BUY	$223.92 - $287.77 $378,424 - $486,331	1,690 New	1,690 $405,000

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $23B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nwam LLC with notifications on news.

Account